Generative AI drug design powered by first-principles target modeling, automated in vitro validation, and minimization of adverse effects through proprietary, knowledge-based metabolic and off-target databases.
3MAGIS’s AI-powered tools, based on first principles, revolutionize the current drug discovery process with a focus on minimizing toxicity and side effects. Real-world validation through in-vitro feedback ensures the reliability and effectiveness of our models.
By leveraging our platform, we have identified new leading candidates and found novel indications for existing or approved drugs in the areas of oncology and rare diseases. The most promising compounds are currently undergoing in vitro validation and optimization of their ADMET properties.
Our platform is particularly well suited to design therapeutics for low population diseases, especially those involving protein targets that are considered untargetable. We actively seek collaborations with private and academic partners for these projects.
High-throughput design and screening of small molecule and bRo5 drug candidates, accomplished through a cloud-native, end-to-end pipeline running on our cluster. The top new candidates are tested in a highly automated fashion in both our laboratory and our partners’ facilities.
01 / LLM-based scientific data mining
02 / Target identification and modeling
03 / High–throughput generation and screening
04 / ADMETox and metabolism modeling
05 / Drug scalability assessment
06 / In vitro validation
01 / LLM-based scientific data mining
02 / Target identification and modeling
03 / High–throughput generation and screening
04 / ADMETox and metabolism modeling
05 / Drug scalability assessment
06 / In vitro validation
Pediatric Acute Myeloid Leukemia: Accelerating the discovery of low-toxicity drug candidatesI
bRo5: Building a platform for high-throughput development of PROTACs and molecular gluesI
ADMETox: Predicting clinical toxicity from first principlesA
Founder
Founder
Biology
Wet Lab
BD
BD
Biology
Wet Lab